Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 9/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30766052 | 0.86 | KLK7 (0.42) | KLK7KLK5ELANEBCHE | |
| SCHEMBL30765476 | 0.80 | ELANE (0.40) | KLK7KLK5ELANEBCHE | |
| SCHEMBL30766013 | 0.80 | KLK7 (0.40) | KLK7KLK5ELANE | |
| SCHEMBL30765726 | 0.77 | BCHE (0.44) | ELANEBCHE | |
| SCHEMBL30765638 | 0.76 | GAA (0.41) | KLK7KLK5ELANEBCHE | |
| SCHEMBL30765784 | 0.75 | NPSR1 (0.35) | ELANEBCHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30765813 | 0.75 | ELANE (0.42) | KLK7KLK5ELANEBCHE | |
| SCHEMBL30765664 | 0.74 | BCHE (0.44) | KLK7KLK5ELANEBCHE | |
| SCHEMBL30765526 | 0.73 | KDM4C (0.46) | ELANEMEN1KMT2A | |
| SCHEMBL30765493 | 0.72 | BCHE (0.44) | KLK7KLK5ELANEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |